Drug intelligence / Profile preview

THYTREG

Development stage: Unknown
Lead developer: Fundación Gregorio Marañón
Modality: Cell Therapies
Administration: Intravenous

Overview

THYTREG is an autologous cell therapy consisting of thymic regulatory T cells (Tregs) that are isolated from the patient's own thymus tissue, which is typically removed during pediatric cardiac surgery. These cells are expanded ex vivo using interleukin-2 (IL-2) and subsequently transfused back into the infant at the time of heart transplantation. The therapy is designed to prevent graft rejection and restore immunological homeostasis by suppressing the recipient's immune response against the donor organ, potentially reducing the requirement for long-term systemic immunosuppression in pediatric patients.

Other names: autologous thymic regulatory T cellsthyTregautologous IL-2–expanded thymic regulatory T cells

Beyond the preview

Go deeper on THYTREG.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THYTREG.

Explore the full profile